2022
A novel human laboratory alcohol self-administration paradigm for medication screening: Modeling the ability to resist drinking and heavy drinking
McKee SA, Verplaetse TL. A novel human laboratory alcohol self-administration paradigm for medication screening: Modeling the ability to resist drinking and heavy drinking. Drug And Alcohol Dependence Reports 2022, 4: 100085. PMID: 36120181, PMCID: PMC9481061, DOI: 10.1016/j.dadr.2022.100085.Peer-Reviewed Original ResearchAlcohol use disorderAlcohol self-administration paradigmSelf-administration paradigmHeavy drinkingAlcohol consumptionMore alcoholAd libitum alcohol consumptionBlood alcohol levelsCross-over designPercent of participantsPreferred alcoholic beverageSelf-administration modelAlcoholic beveragesMedication screeningMedication signalsUse disordersAlcohol levelsGreater cravingFirst drinkDrinkingStress imageryParticipants
2020
A Critical Review of Alcohol Administration Guidelines in Laboratory Medication Screening Research: Is It Time to Include Treatment Seekers?
Roberts W, Verplaetse TL, Ramchandani VA, McKee SA. A Critical Review of Alcohol Administration Guidelines in Laboratory Medication Screening Research: Is It Time to Include Treatment Seekers? Alcohol Clinical And Experimental Research 2020, 45: 15-24. PMID: 33190310, PMCID: PMC7855436, DOI: 10.1111/acer.14514.Peer-Reviewed Original ResearchConceptsHuman laboratory studiesTreatment seekersNontreatment seekersExpensive clinical trialsPatient populationAlcohol administrationClinical trialsMedication effectsClinical conditionsMedication developmentMedicationsHeavy drinkersMedication experimentsLaboratory screeningClinical realityAdministration guidelinesScreening researchDevelopment pipelineLaboratory studiesRiskGuidelinesParticipantsPharmacotherapyPopulationEthical guidelines
2018
A preliminary investigation into the effects of doxazosin on cognitive functioning in tobacco‐deprived and ‐satiated smokers
Roberts W, Verplaetse TL, Moore KE, Oberleitner LM, McKee SA. A preliminary investigation into the effects of doxazosin on cognitive functioning in tobacco‐deprived and ‐satiated smokers. Human Psychopharmacology Clinical And Experimental 2018, 33: e2660. PMID: 29878501, PMCID: PMC5995328, DOI: 10.1002/hup.2660.Peer-Reviewed Original ResearchConceptsContinuous performance taskInhibitory controlCognitive functioningPerformance taskTobacco withdrawalEffects of doxazosinSustained attentionCognitive performanceWithdrawal symptomsCognitive AssessmentSmoking outcomesMost measuresSelf-reported withdrawal symptomsReaction timeTaskParticipantsFunctioningPredrug levelsΑ1 antagonistTitration periodGreater improvementDoxazosinSmokingSymptomsPreliminary investigation